Intellia Therapeutics Inc. — Sponsor Intelligence | 7 EU Trials

Filter these 7 trials by condition, phase, country and more.

7 Registered trials

2 Recruiting

4 Completed trials

15 Countries active

10 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase I/II

Phase I

Phase I (FiH)

Oversight events:

14 temporary halts 1 corrective measure across 1 trial

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

Top indications

7 total

Long-Term Follow-Up of Subjects Treated With NTLA-2002 Recruiting

2023-507956-56-00 Phase I/II 3 countries ZICLUMERAN, LONVOGURAN
Long-Term Follow-Up of Subjects Treated With NTLA-2001 Recruiting

2023-507385-11-00 Phase II/III 2 countries ZICLUMERAN, SINGLE GUIDE RNA TARGETING THE HUMAN TTR GENE
A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) Ended

2024-515741-42-00 Phase III 3 countries ZICLUMERAN, LONVOGURAN
A Study to Evaluate NTLA-2002 in adults with Hereditary Angioedema (HAE) Ended

2024-512317-40-00 Phase I/II 3 countries ZICLUMERAN, LONVOGURAN
A Phase 3 Study of NTLA 2001 in participants with amyloidosis with cardiac muscle disease. Halted

2023-507220-23-00 Phase III 14 countries CETIRIZINE DIHYDROCHLORIDE; DEXAMETHASONE; FAMOTIDINE; PARACETAMOL; ZICLUMERAN, …
NTLA-2001 in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN) Ended

2024-511170-69-00 Phase I 2 countries ZICLUMERAN, SINGLE GUIDE RNA TARGETING THE HUMAN TTR GENE
A Phase 1/2 Study of NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease Ended

2023-508138-33-00 Phase I (FiH) 1 country MESSENGER RNA ENCODING CAS9, SINGLE GUIDE RNA CONTAINING A SEQUENCE COMPLEMENTAR…

Showing 1–7 of 7 trials